FDA approves supplemental patient cohort for HeartWare's Endurance trial


The FDA approves and IDE supplement allowing HeartWare International (HTWR -0.6%) to enroll an additional patient cohort for the Endurance destination therapy study.

Data from the new cohort will be included in a PMA application seeking a destination therapy indication for the HeartWare System. (PR)

More on the Endurance trial: Northland sees "glaring inconsistencies."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs